Refine by
Immunotherapeutic Suppliers In Germany
8 companies found
based inMonmouth Junction, NEW JERSEY (USA)
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 58 countries around the world, as an extracorporeal ...
based inBerlin, GERMANY
JPT Peptide Technologies GmbH is a leading provider of custom peptides and innovative peptide-based services and products. We are a research and development partner for projects in immunotherapy and vaccine Development, immune monitoring, proteomics ...
Clinical peptides and PepMix Peptide Pools are increasingly needed as antigen source for clinical immune monitoring, diagnostics, cell therapy and vaccine development. The diversity of applications and regulatory requirements calls for a flexible, ...
based inFreiburg, GERMANY
Sartorius CellGenix is a leading global supplier of high quality raw and ancillary materials for the expanding market of cell and gene therapy and regenerative medicine. We develop, manufacture and market human cytokines, growth factors, and other ...
CellGenix GMP DC is an optimized, serum-free medium used for the generation of human dendritic cells (DCs). It promotes high yields of mature dendritic cells with the desired ...
based inOststeinbek / Hamburg, GERMANY
ROXALL is an international active pharmaceutical company based in Hamburg, Germany. The main focus is the development, production and distribution of products in the field of allergology, immunology and emergency medicine. With innovations in ...
Allergies can be treated in different ways. In comparison to medicine that treats merely the symptoms without regarding the cause of the decease the specific Immunotherapy (SIT) is the only way to build up an immunologic tolerance to the allergens ...
based inPlanegg, GERMANY
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines. At MorphoSys, our ambition is to redefine how cancer is treated. As a commercial-stage biopharmaceutical ...
Tafasitamab (MOR208) is a humanized FC-modified CD19 targeting immunotherapy in clinical development for the treatment of B cell malignancies. CD19 is broadly expressed on the surface of B cells. It is therefore considered as a potential target for ...
based inBaldham, GERMANY
ORYX’ development strategy bridges the gap between academic research and the pharmaceutical industry for new cancer therapies. Today, the company is developing three clinical cancer immunotherapy projects in indications with high unmet medical need. ...
ParvOryx is an oncolytic parvovirus H1 (H-1PV), a wild type rat virus that infects and lyses tumor cells from a wide variety of cancers. These tumor types include glioblastoma multiforme, pancreatic cancer, breast cancer, lung cancer, melanoma, ...
based inDessau-Rosslau, GERMANY
IDT Biologika is an international leader in the contract development and manufacture of Viral Vaccines, Viral Vectors for Gene and Immune Therapeutics, Oncolytic Viruses, Virus-Like Particles, and other biologics. We are a full-service biologics ...
IDT Biologika is a leading viral vector CDMO with an exceptional track record in biologics manufacturing, including expertise with live viral agents. This makes us well-positioned to support the rapid growth in gene therapy and ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
ACTallo® is a process developed by Immatics for the manufacture of allogeneic, off-the-shelf, TCR-engineered cellular therapies derived from healthy donors’ gamma delta T ...